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salvator@jhmi.eduAbstractGH and its principal mediator IGF1 have important effects on metabolic and cardiovascular
(CV) status. While acquired GH deficiency (GHD) is often associated with increased CV risk,
the consequences of congenital GHD are not known. We have described a large group of
patients with isolated GHD (IGHD) due to a homozygous mutation (c.57C1GOA) in the
GH releasing hormone receptor gene, and shown that adult GH-naı¨ve individuals have no
evidence of clinically evident premature atherosclerosis. To test whether subclinical
atherosclerosis is anticipated in untreated IGHD, we performed a cross-sectional study of
25 IGHD and 27 adult controls matched for age and gender. A comprehensive clinical and
biochemical panel and coronary artery calcium scores were evaluated by multi-detector
tomography. Height, weight, IGF1, homeostasis model assessment of insulin resistance,
creatinine and creatininekinase were lower in the IGHD group. Median and interquartile
range of calcium scores distribution was similar in the two groups: IGHD 0(0) and control
0(4.9). The vast majority of the calcium scores (20 of 25 IGHD (80%) and 18 of 27 controls
(66.6%)) were equal to zero (difference not significant). There was no difference in the
calcium scores classification. None of IGHD subjects had minimal calcification, which were
present in four controls. Three IGHD and four controls hadmild calcification. There were two
IGHD individuals with moderate calcification and one control with severe calcification.
Our study provides evidence that subjects with congenital isolated lifetime and untreated
severe IGHD do not have accelerated subclinical coronary atherosclerosis.Key Words
" coronary atherosclerosis





(2016) 5, 41–46IntroductionGrowth hormone (GH) and its principal mediator insulin-
like growth factor 1 (IGF1) have important effects not only
on the acquisition of normal body size, but also on
metabolic and cardiovascular (CV) status (1). GH andIGF1 have synergistic anabolic effect on muscle mass, but
antagonist effects on insulin action (GH-reducing and IGF1
increasing insulin sensitivity) and lipolysis (GH increasing
and IGF1 reducing it) (2). Adult onsetGHdeficiency (GHD)sed under a Creative Commons
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2–6 5 :42has been described as model of metabolic syndrome, with
visceral obesity, insulin resistance, endothelial dysfunc-
tion, increased sympathetic activity, and a pro-inflam-
matory profile (3, 4, 5). Although GH replacement therapy
has been shown to reduce the risk profile (6), it is still
unclear if this is due to GHD per se, or to confounding
factors often found in acquired GHD (other pituitary
hormone deficiencies, inadequate replacements and
pituitary surgery or radiotherapy) (7, 8).
A model of isolated GHD (IGHD) would be preferable
to study the relationship between the GH–IGF1 axis and
CV risk. In Itabaianinha county, in the northeastern
Brazilian state of Sergipe, we have described a large
group of subjects with familial IGHD due to a homozygous
(c.57C1GOA) mutation in the GHRH receptor gene
(GHRHR) (9). The untreated IGHD adults have propor-
tionate dwarfism, and otherwise normal pituitary function
(10). They exhibit a balance between adverse and
beneficial CV risk factors. The adverse factors are increased
systolic blood pressure (BP), higher fat mass percentage,
increased total and LDL-cholesterol and C-reactive protein
(11), visceral obesity and elevated cortisol to cortisone
ratio (12). The protective factors include normal serum
leptin, increased adiponectin (13) and increased insulin
sensitivity (14). The adult IGHD individuals do not present
premature clinical carotid (15) or aortic atherosclerosis
(16) nor coronary ischemia assessed by stress echocardio-
graphy (15, 17), and have similar longevity as non-affected
siblings (18). Because coronary disease presents with a
long latency period, it is important to know if subclinical
atherosclerosis exists in these IGHD subjects. To answer
this, it is necessary to assess asymptomatic individuals
(19, 20, 21). Measurement of coronary artery calcium by
multi-detector tomography has been shown to predict the
risk of clinical coronary disease (22, 23, 24, 25). This study
tested whether subclinical atherosclerosis is accelerated in
these IGHD asymptomatic individuals by comparing
calcium scores in IGHD and normal controls.Subjects and methods
Subjects
In a cross-sectional study, asymptomatic IGHD and age-
and sex-matched control subjects (controls) were recruited
by advertising in the local Dwarfs Association building
and by word of mouth among the inhabitants of
Itabaianinha. Inclusion criterion for IGHD was genotype-
proven homozygosity for the c.57C1GOA GHRHR
mutation, whereas controls were normal staturedhttp://www.endocrineconnections.org
DOI: 10.1530/EC-15-0118
 2016 The authors
Published by Bioscientifica Ltd.individuals proven to be homozygous for the wt GHRHR
allele. Exclusion criteria were: previous GH treatment, age
under 18 years, CV symptoms or any evidence of active
CV diseases. Twenty-five (13 females) IGHD and 27
(15 females) volunteered and were enrolled. None of
these IGHD individual have participated in a previous
6-month GH depot trial (17). The Federal University of
Sergipe Institutional Review Board approved these studies
and all subjects gave written informed consent.Interview and physical examination
The subjects were submitted to a detailed interview
including risk factors for CV disease, hypertension,
smoking, dyslipidemia, familiar CV history, co-morbidi-
ties and treatments, and to a physical examination, with
measurement of body weight and height. BP was obtained
by the average of three measurements obtained in the left
arm after 10 min of rest in the sitting position by one
physicians (U M M C) using a mercury sphygmomano-
meter with a cuff appropriate for the size of the arm.
The Framingham risk score was estimated (26).Laboratory assessment
Blood was collected after an overnight fast. Total
cholesterol, triglycerides, glucose, insulin, urea, creatinine
and creatinine kinase were measured by standard tech-
niques. The increase in total cholesterol in this IGHD
cohort is due to an increase in LDL cholesterol (11, 13, 15).
IGF1 was measured by a solid-phase, enzyme-labeled
chemiluminescent immunometric assay (IMMULITE
2000, Siemens Healthcare Diagnostics Products Ltd,
Malvern, PA, USA), with intra- and inter-assay variabilities
of 3.1 and 6.1% respectively. Insulin was measured by a
solid-phase, enzyme-labeled chemiluminescent immuno-
metric assay (IMMULITE 2000 Siemens Healthcare
Diagnostics Products Ltd), with intra- and inter-assay
variabilities of 4.2 and 5.1% respectively. Insulin resist-
ance was estimated using the homeostasis model assess-
ment of insulin resistance (HOMAIR) with the formula:
fasting serum insulin (mlU/ml) x fasting plasma glucose
(mmol/l)/22.5. All the tests were carried out in the
Laboratory of University Hospital of the Federal University
of Sergipe, in Aracaju, Sergipe.Coronary tomography for calcium score
Calcium score was calculated with the use of a 64-slice
multi-detector tomography scanner (Siemens Somatom
Definition AS) dedicated to ECG-synchronized cardiacThis work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International License.
Table 2 Classification of calcium scores in IGHD and controls.
Calcium score IGHD (25) Controls (27)
0 (absent) 20 18
1–10 (minimal) 0 4
11–100 (mild) 3 4
101–300 (moderate) 2 0
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Syngovia software (Siemens Healthcare Global) was
employed to acquire the Agatston score. All computed
tomographies were analyzed by a single reader. The
classification of calcium score followed the American
College of Cardiology/American Heart Association Task
Force criteria. Calcium score O300Zsevere calcification,
101–300Zmoderate calcification, 11–100Zmild calcifica-
tion, 1–10Zminimal calcification and 0Zabsence of
calcification (25).Statistical analysis
Data are expressed as mean (S.D.), except for IGF1,
insulin, HOMAIR and calcium scores expressed as median
(interquartile range). Student’s t-test was used for variables
with normal distribution, and Mann–Whitney U-test for
variables without Gaussian distribution (IGF1, insulin,
HOMAIRandcalciumscores). Fisher’s exact testwasused to
analyze classification of CAC sores and percentage of
previous smoking, high BP and diabetes. Statistical analysis
was performed using the statistical software SPSS 19.0
version. P values under 0.05 were considered significant.Results
Table 1 shows the clinical and biochemical features of
the two groups. Height, weight, IGF1, insulin, HOMAIR,
creatinine, creatininekinase andwere lower in IGHD group.Table 1 Clinical and biochemical features of IGHD and control
subjects.
IGHD (25) Control (27) P
Age (years) 50.1 (15.9) 51.1 (14.0) 0.799
Sex (F/M) 13/12 15/12 0.764
Smoking 1 2 1
Weight (kg) 39.3 (8.7) 71.8 (14.4) !0.0001
Diabetes history 4 2 0.411
Dislipidemia history 11 11 1
Arterial hypertension 8 16 0.058
Height (m) 1.2 (0.18) 1.6 (0.1) !0.0001
BMI (kg/m2) 25.5 (5.7) 26.7 (4.2) 0.402
Systolic BP (mmHg) 122.1 (18.9) 124.4 (15.0) 0.622
Diastolic BP (mmHg) 78.8 (9.3) 80.4 (6.5) 0.486
IGF1 (ng/ml) 1.9 (0) 132 (55) !0.0001
Glucose (mg/dl) 105.5 (22.7) 105.9 (70.5) 0.975
Insulin (mUI/ml) 5.35 (3.8) 17.3 (10.9) !0.0001
Homa IR 1.4 (1.0) 4.3 (3.1) 0.012
Cholesterol (mg/dl) 227.0 (65.1) 210.7 (28.2) 0.257
Tryglicerides (mg/dl) 142.0 (95.5) 135.3 (51.3) 0.762
Urea (mg/dl) 38.6 (9.8) 34.7 (9.0) 0.143
Creatinine (mg/dl) 0.7 (0.1) 0.9 (0.2) !0.0001
Creatininekinase (IU/l) 82.0 (35.1) 152.8 (141.0) 0.017
Framingham score 5.7 (6.4) 4.9 (4.5) 0.596
http://www.endocrineconnections.org
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Published by Bioscientifica Ltd.Table 2 shows the calcium scores. The distribution
expressed as median and interquartile range was similar in
the two groups: IGHD 0(0) and control 0(4.9). The vast
majority of the CAC scores (20 out 25 IGHD (80%) and 18
out 27 controls (66.6%)) were equal to zero, pZ0.354. The
highest CAC scores were 128.1 in IGHD and 331.5 in
controls. Two subjects were further evaluated. A 66-year-
old IGHD female (with compliant of chest pain) under-
went CT angiography and coronary angiogram, and
a clinical three arterial lesion was found. The second, a
61-year-old control male exhibited normal exercise stress
echocardiography. Both were recommended lifestyle
modifications and statin use.Discussion
Acquired adult-onset GHD is a model of metabolic
syndrome, with abdominal obesity, insulin resistance
and dyslipidemia (3, 4, 5). Nevertheless, the relationship
between GHD and obesity includes several mechanisms
and including some degree ofGH resistance in obesity (27).
Although GH replacement therapy has been shown to
reduce this risk profile (6), it is still unclear if the high risk
is due to untreated GHD, or to confounding factors often
found in acquired GHD. Some of these factors such as
hypogonadism, excessive glucocorticoid replacement,
craniopharyngioma, radiotherapy (implicated in cerebro-
vascular mortality or de novo brain tumors) and very
recently adrenal crisis (7, 8, 28, 29, 30, 31, 32, 33) have
been implicated in the increased mortality risk associated
with hypopituitarism (28). Accordingly, very recent
national or multicenter studies have suggested that GHD
deficiency in the context of hypopituitarism does not
cause an increase in CV mortality despite increased
general mortality risk (8, 29, 30).
As our previous studies indicated that this IGHD group
has no premature clinical atherosclerosis (11, 15, 16, 17),
we decided to assess subclinical atherosclerosis, by
measuring the calcium content in the coronary arteries.
Calcium score is an independent predictor of mortality in
a multivariable model controlling for age, gender,This work is licensed under a Creative Commons
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provide additional risk prediction beyond the Framing-
ham risk score in individuals with low and high CV risk
(22, 23). Most of our IGHD and controls present with
calcium score of zero. In subjects with positive values, the
majority had mild calcification. There were two IGHD
individuals with intermediate calcification (one of them
underwent coronary angiography that showed non-critic
lesions), and one control with severe calcification (had no
symptoms, underwent to resting and exercise echocardio-
graphy that showed no ischemia). The lack of subclinical
atherosclerosis corroborates our previous finding that
congenital IGHD is not a cause of CV mortality (17).
The calcium scores of IGHD individuals expressed as
percentage of the negative scores and the median and
interquartile range (80% and 0(0)) are very similar to ones
of a Portuguese cohort (Lisbon) of asymptomatic normal
individuals (82% and 0(0)). Our control values (66.6% and
0(4.9)) were similar to the ones observed in area of
southern Brazil (Sao Paulo) (54% and 1(0.68)), and lower
than the ones observed in mainland USA (Columbus,
Ohio and Nashville, Tennessee) (46% and 4(0.87)), in
pooled genders (34). Because the state of Sergipe is one of
the regions where the Portuguese colonization of Brazil
had begun, 60% of the population is of Portuguese origin
(35). It is possible that the Portuguese ancestry influenced
the calcium scores in both IGHD and controls. However,
as calcium scores parallel the CV mortality rates in the
three nations (34), we can conclude that IGHD subjects
have an atherosclerosis risk that is similar to non-GHD
asymptomatic normal individuals form the same region.
Both IGHD and control groups have low Framingham
risk scores, despite the fact that the IGHD group is exposed
to higher burden of classical CV risks throughout life
(in this particular sample the prevalence of hypertension
was not different between the two groups). One expla-
nation for this finding is the increased insulin sensitivity
of IGHD subjects despite visceral adiposity (12). Another
possible explanation lies on the degree of IGF1 reduction.
It is possible that different degrees of IGF1 deficiency may
result in different effects on the vascular wall (15). Mild
IGF1 reduction in the general population has been linked
to increased risk ischemic heart disease (36). Conversely,
very severe IGF1 reduction, as found in our IGHD model,
may be protective against atherosclerosis. This fits with
the increase longevity of animal models of GHD or GH
resistance (37). Accordingly, when we treated a subset of
these patients with submaximal doses of GH for 6months,
converting a severe in a mild IGF1 deficiency we observed
the appearance of atherosclerotic plaques (17).http://www.endocrineconnections.org
DOI: 10.1530/EC-15-0118
 2016 The authors
Published by Bioscientifica Ltd.Calcium scores of patients with IGHD due to large
homozygous deletions in the GH-1 gene, or with GH
resistance (Laron dwarfism) are not available to compare
the frequency of subclinical atherosclerosis in these
models with ours. Longevity, influenced not only by
clinical atherosclerosis, but also from other conditions
such as cancer, infectious diseases and accidents, seems to
be reduced in the formermodel (38), but is not in the latter
(39). Differently from subjects with large deletions in the
GH-1 gene (complete lack of GH secretion) and Laron
dwarfism (lack of GH action), our IGHD subjects have very
low, but detectable serum GH levels (10). This residual GH
secretion may exert some metabolic actions, resulting in
differences between these disease models.
One limitation of our study is that the age of our
sample is relatively young.However, near 80%of the IGHD
subjects are S35 years, age sufficient in other studies to
identify individuals who have subclinical atherosclerosis
when CV risk factors are present (40, 41). It is also possible
that subjects with worse health status would not have
volunteered.
Other factors that may influence the development of
atherosclerosis include environmental factors and
dietary habits. Both GHD and controls reside in the same
area, which is becoming progressively more urbanized.
While we have recently reported that GHD subjects
consume in percentage more proteins, less carbohydrates
and equal amount of lipids in comparison with the
controls (42), it is difficult to predict the role of such
dietary differences on the development of subclinical
coronary atherosclerosis.
In conclusion, subjects with congenital isolated life-
time and untreated severe IGHD do not have accelerated
subclinical coronary atherosclerosis when compared with
the normal controls from the same region.Declaration of interest
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